Alumis, Inc. (ALMS)
23.62
+0.58
(+2.54%)
USD |
NASDAQ |
Aug 25, 12:14
Alumis EPS Diluted (Quarterly) : -1.114 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.114 |
| March 31, 2026 | -0.7441 |
| December 31, 2025 | -0.8875 |
| September 30, 2025 | -1.064 |
| June 30, 2025 | 0.7741 |
| March 31, 2025 | -1.823 |
| December 31, 2024 | -1.742 |
| Date | Value |
|---|---|
| September 30, 2024 | -1.712 |
| June 30, 2024 | -1.039 |
| March 31, 2024 | -0.9615 |
| December 31, 2023 | -0.758 |
| September 30, 2023 | -0.8367 |
| June 30, 2023 | -0.70 |
| March 31, 2023 | -0.6949 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Corcept Therapeutics, Inc. | 0.356 |
| Aclaris Therapeutics, Inc. | -0.1507 |
| Crinetics Pharmaceuticals, Inc. | -1.145 |
| Tarsus Pharmaceuticals, Inc. | -0.4275 |
| Structure Therapeutics, Inc. | -1.464 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -142.22M |
| Revenue (Quarterly) | 1.662M |
| Total Expenses (Quarterly) | 143.88M |
| Enterprise Value | 2.494B |
| Gross Profit Margin (Quarterly) | 47.41% |
| Profit Margin (Quarterly) | -8.56K% |
| Earnings Yield | -16.13% |
| Normalized Earnings Yield | -14.83 |